



For Immediate Release

H&T Corporation  
2-20-4 Morikawachi-nishi, Higashi-Osaka City, Osaka 577-0061 JAPAN  
TEL: 81-6-6785-3322 / FAX: 81-6-6785-3435  
Email: [handt@ht21.co.jp](mailto:handt@ht21.co.jp) Website: <http://www.ht21.co.jp/>

### H & T Receives Investment of 20 Million Yen from Kinki-Osaka Fund No. 1

(January 17, 2008 - Osaka, Japan) – On December 26, 2007, the H & T Corporation received an investment of 20 Million yen from the Resona Capital Co., Ltd. (managing party of Kinki-Osaka Fund No. 1) through the allocation of shares to a third party. As a result of this investment, H&T's capital has grown from 145 million yen to 155 million yen, with 98 million yen of reserve capital. This investment fund will be directed toward the further development of H&T's pharmaceutical safety trial support system.

The H&T Corporation was founded in 1998, and is currently working on the development of its "TOX-LAUNCHER" preclinical data collection system. The system, which is sold as packaged software, gathers and compiles data from the preclinical animal testing stage in the development of new pharmaceutical products. The system is compliant with both Good Laboratory Practice (GLP) and FDA21 CFR Part11 regulations, and can be used to realize reductions in the cost and labor involved with administering preclinical trials. With novel features such as the system's selectable installation format, which allows the user to choose from various menus only those system components that are necessary for his or her particular study, and the system's 'Auto-Validation' function, which automatically performs Operational Qualification (OQ) for the system, the user is given flexibility in both system installation and operation.

The system is three fifths complete, with Japanese language versions of the Pathology Subsystem, Weight Measurement Subsystem, and Clinical Pathology Subsystem all available for purchase, and has already received high praise from pharmaceutical companies that have had the system installed. With the increase in capital mentioned above, the company is aiming to accelerate the development of the two remaining subsystems (the Clinical Observation Subsystem and the Reproductive Toxicity Test Subsystem) and complete the entire system ahead of schedule.